Compare TX & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TX | ICLR |
|---|---|---|
| Founded | 1961 | 1990 |
| Country | Luxembourg | Ireland |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.3B |
| IPO Year | 2006 | 2001 |
| Metric | TX | ICLR |
|---|---|---|
| Price | $49.74 | $158.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $37.70 | ★ $178.62 |
| AVG Volume (30 Days) | 625.9K | ★ 784.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.60 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $20.15 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.44 | $66.57 |
| 52 Week High | $51.73 | $203.91 |
| Indicator | TX | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 67.18 | 44.15 |
| Support Level | $41.60 | $157.06 |
| Resistance Level | $50.35 | $191.33 |
| Average True Range (ATR) | 1.32 | 7.74 |
| MACD | 0.53 | -2.04 |
| Stochastic Oscillator | 91.67 | 6.48 |
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.